What Cogstate Ltd. does

Cogstate Ltd. is a publicly traded (ASX: CGS, OTC: COGZF) digital cognitive assessment company that builds and commercializes validated electronic cognitive testing batteries, rater training programs, and monitoring solutions for use in central nervous system (CNS) clinical trials. The company's platform delivers cognitive assessments through a unified electronic clinical outcome assessment (eCOA) architecture that supports both site-based and decentralized trial environments, and is positioned as one of three primary global platform providers alongside Pearson Clinical Assessment and Cambridge Cognition. Its core technology stack emphasizes accuracy, endpoint integrity, and regulatory-grade validation across indications including early-stage Alzheimer's, broader CNS disorders, sleep medicine, and Long COVID.

The company sells primarily to enterprise pharmaceutical and biotechnology sponsors conducting CNS clinical trials, as well as clinical research organizations (CROs) that operationalize those trials. Cogstate generates revenue through contract-based clinical trial services that are recurring in nature, with pricing quote-based and not publicly disclosed. Its go-to-market combines direct enterprise field sales targeting pharma/biotech sponsors with strategic channel partnerships, most notably the integration of its assessments into Medidata's unified eCOA platform and THREAD's decentralized research platform, both formalized in 2024. Cogstate also invests in thought leadership, with Chief Innovation Officer Prof. Paul Maruff presenting frameworks for cognitive endpoint selection at industry webinars.

Operationally, Cogstate is headquartered in New Haven, United States, employs between 101 and 250 people, and reported a 12% year-over-year revenue increase in Q2 2026 alongside record trial starts and an expanded customer base, while maintaining strong financial margins. Leadership comprises CEO Brad O'Connor, CTO Ben Bloomfield, CFO Darren Watson, Chief Commercial Officer Kenneth Billard, Chief Scientific Officer Chris Edgar, and Chief Innovation Officer Prof. Paul Maruff.

Name

Cogstate Ltd.

Legal name

Cogstate Limited

Website

https://cogstate.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

101–250 employees

Short description

Cogstate Ltd. builds validated digital cognitive assessments, rater training, and eCOA solutions for pharmaceutical, biotech, and CRO customers running CNS clinical trials, distributing through Medidata and THREAD integrations.

Ownership category

akta.pro rank

Product category

Clinical Trial Cognitive Assessment Software

NAICS

Scientific Research and Development Services (5417), Testing Laboratories and Services (54138), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industries

Clinical Trial Management Systems (CTMS) (HLACAOAD), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Diagnostic & Triage Decision Support (HLACAGAA)

Keywords

• Digital cognitive assessment
• Clinical outcome assessments
• CNS clinical trials
• ECOA platform
• Decentralized clinical trials

Headquarters

HQ city

New Haven

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Clinical Trial Services: Revenue generated from pharmaceutical and biotech companies contracting for cognitive assessment services in clinical trials, with 12% revenue increase in Q2 2026 driven by growth in clinical trial contracts and diversification into new therapeutic indications.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Cogstate designs and delivers validated digital cognitive assessments paired with rater training and monitoring solutions that are integrated into electronic Clinical Outcome Assessment (eCOA) platforms used in central nervous system (CNS) clinical trials. Its solutions support pharmaceutical, biotech, and CRO customers running decentralized trials across therapeutic areas such as Alzheimer's disease and sleep-wakefulness disorders. The company combines proprietary assessment batteries, eCOA delivery technology, and clinical-development expertise as a contracted service to trial sponsors.

Differentiator

Problem solved

Functional benefit

Products and services

• Validated Digital Cognitive Assessments Validated digital cognitive assessments delivered to pharmaceutical, biotech, and CRO customers for use in central nervous system (CNS) clinical trials, designed to preserve endpoint integrity and data quality across sites.
• Rater Training and Monitoring Solutions Comprehensive rater training and monitoring solutions used by clinical trial sponsors to ensure cognitive assessment consistency and endpoint quality across global CNS trial sites.
• Decentralized eCOA Delivery for CNS Trials Flexible electronic Clinical Outcome Assessment delivery supporting decentralized CNS clinical trial environments, enabling broader reach and site flexibility for trial sponsors.
• Cognitive Framework for Sleep-Wakefulness Drug Evaluation A domain-specialized cognitive assessment framework that addresses inconsistent terminology and aligns subjective and objective cognitive measurement for sleep medicine clinical development teams.

Quantifiable outcome

• Reduced variability and administrative burden in CNS clinical trials
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• MedidatacoreTechnology or Integration · 1 October 2024Strategic partnership integrating Cogstate's validated digital cognitive assessments, rater training, and monitoring solutions into Medidata's unified eCOA platform. A case study involving a Long COVID study conducted with a clinical-stage biopharmaceutical company demonstrated how consolidating multiple assessment types onto a single device streamlined site operations and improved data integrity.
• THREAD, Inc.coreTechnology or Integration · 1 July 2024Partnership to combine Cogstate's digital assessment capabilities with THREAD's decentralized research platforms for central nervous system disorders, enabling more flexible eCOA delivery in decentralized trial environments.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• THREAD, Inc. Decentralized clinical trial platform partner (announced Jul 2024); both an integration partner and an emerging platform competitor in decentralized CNS trial delivery.
• Cerveau Technologies: Emerging player in CNS clinical research services providing imaging biomarkers and CNS trial support for neurodegenerative disease programs, partially overlapping Cogstate's CNS trial endpoint focus.

Broad incumbents

• IQVIA: Global CRO and clinical technology provider offering eCOA, CNS trial services, and decentralized trial platforms; represents both a large competitor and potential enterprise customer for cognitive assessment solutions.
• Evidera (PPD/Pharmaceutical Product Development): Large CRO providing clinical outcome assessment and CNS endpoint services for pharmaceutical sponsors; competes for similar pharma/biotech contracts with cognitive and functional endpoint offerings.
• Clario: Broad clinical trial technology incumbent providing eCOA, imaging, and CNS assessment solutions across multiple therapeutic areas; competes with Cogstate's eCOA-integrated cognitive assessment offering for enterprise pharma sponsors.
• Medidata Solutions: Industry-leading eCOA and clinical trial technology platform; both a strategic partner (via integration) and a competitive threat if it expands its own cognitive assessment capabilities in CNS.
• WCG (WIRB-Copernicus Group): Clinical services provider offering CNS clinical trial solutions, rater training, and eCOA-related services that overlap with Cogstate's enterprise CNS assessment offering.

Direct peers

• Pearson Clinical Assessment: Direct competitor providing validated cognitive assessment solutions for clinical trials; named alongside Cogstate and Cambridge Cognition as one of the three primary global platform providers.
• Cambridge Cognition: Direct competitor in digital cognitive assessment for CNS clinical trials; explicitly named alongside Cogstate as one of the three primary global platform providers in the cognitive assessment market.
• Signant Health (formerly MedAvante-ProPhase): Direct competitor offering eCOA, rater training, and CNS clinical outcome assessment services for pharmaceutical trials; overlaps with Cogstate's rater training and monitoring solutions in CNS indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Cogstate
• Facebookfacebook.com/CogState
• LinkedInlinkedin.com/company/1145063

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cogstate Ltd.